AUS
NZ
UK
CA
USA
IND
Highlights:
- Belite Bio doses first patient in Phase 2/3 DRAGON II trial for Stargardt disease.
- $28.75 million raised from warrant exercises strengthens balance sheet.
- R&D expenses decreased by $1.9 million year-over-year, signaling cost efficiency.
Belite Bio (NASDAQ:BLTE), a clinical-stage biopharmaceutical company focused on the development of therapies for retinal diseases, has released its Q3 2024 financial results, showcasing significant clinical progress and a strong cash position. The company continues to advance its pivotal clinical trials and strengthen its financial footing, positioning itself for future growth.
One of the standout achievements for Belite Bio in Q3 2024 was the dosing of the first patient in its Phase 2/3 DRAGON II trial. This study is designed to evaluate the company’s novel treatment for Stargardt disease, a genetic condition that causes progressive vision loss. The DRAGON II trial is a critical milestone in Belite Bio’s ongoing efforts to develop treatments for inherited retinal diseases. The company is optimistic about the potential of its lead candidate to provide meaningful therapeutic benefits for patients suffering from this rare and debilitating condition.
In addition to progress in the Stargardt disease program, Belite also reported strong enrollment in its Phase 3 PHOENIX trial for geographic atrophy (GA), a form of advanced age-related macular degeneration (AMD). Over 280 subjects have been enrolled in the PHOENIX trial, which aims to evaluate the efficacy of Belite’s therapeutic candidate in slowing or halting the progression of GA. The company’s ability to enroll a significant number of participants in this pivotal trial is a positive indicator of the study’s progress and the potential market demand for an effective GA treatment.
As of the end of Q3 2024, Belite Bio maintains a strong cash position of $109.0 million, ensuring that it has the financial resources to support its ongoing clinical trials and operational needs. This solid cash balance is complemented by $28.75 million raised through warrant exercises during the quarter, further strengthening the company’s liquidity.
R&D expenses, which represent a significant portion of Belite Bio’s spending, decreased to $6.8 million in Q3 2024 from $8.7 million in the same period last year. This 22% reduction in R&D costs highlights the company’s ongoing efforts to streamline operations and allocate resources efficiently, even as it advances multiple high-priority clinical programs. Additionally, other income for the quarter increased significantly, rising to $1.1 million compared to just $0.03 million in Q3 2023. This uptick in other income reflects the company’s ability to generate non-operational revenue streams, further bolstering its financial position.
Despite the positive financial metrics, Belite Bio reported a net loss of $8.7 million for Q3 2024, up from a net loss of $7.6 million in the same quarter last year. The company’s net loss for the first nine months of 2024 also increased, rising to $26.0 million from $24.6 million in the prior year. The increase in net loss is primarily due to higher general and administrative (G&A) expenses, which rose to $2.9 million from $2.2 million year-over-year. The increase in G&A expenses can be attributed to the company’s ongoing efforts to build its corporate infrastructure as it advances its clinical pipeline and prepares for future commercialization.
Looking forward, Belite Bio is focused on completing enrollment in its clinical trials and driving progress toward regulatory filings for its therapies. The company expects an interim analysis from its Phase 3 DRAGON trial by the end of 2024 or early 2025, which could provide important insights into the efficacy of its Stargardt disease treatment. With a strong cash position, reduced R&D expenses, and a growing pipeline of clinical programs, Belite Bio is well-positioned to continue making strides in the treatment of retinal diseases.
